BioSpace News Archive

- Top-line results from a Phase 3 study evaluating RINVOQ in moderate to severe atopic dermatitis in adults and adolescents show both doses of upadacitinib (15 mg and 30 mg) monotherapy met all primary and secondary endpoints versus placebo[1] - No new safety risks were observed compared to the safety profile observed in patients with rheumatoid arthritis and psoriatic arthritis receiving RINVOQ[1-5] - RINVOQ, a selective and reversible JAK inhibitor discovered and developed

Catalyst Biosciences, Inc., announced the pricing of an underwritten public offering of 4,615,384 shares of its common stock, offered at a price of $6.50 per share to the public.

Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small-molecule oncology therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for LNS8801 for the treatment of patients with metastatic or unresectable melanoma

Pfizer Inc. (NYSE:PFE) and Sangamo Therapeutics, Inc. (Nasdaq:SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec (SB-525, or PF-07055480), an investigational gene therapy for patients with severe hemophilia A

The gift is part of a $2.5 million SPIE education-funding initiative for optics and photonics

Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that enrollment has begun in the CIRCULATE-Japan and BESPOKE CRC trials, with both studies experiencing stro

Donation to fund additional testing centers, medical staff support and blood drives in underserved and disadvantaged communities

BioInvent International AB (“BioInvent”) (OMXS: BINV) today announces, on behalf of the nomination committee and major shareholders, the proposal to elect Dr. Thomas Hecht as new Board member at the Extraordinary General Meeting on July 3, 2020 , in accordance with the convening notice to the Extraordinary General Meeting.

The Marena Group LLC, a Georgia-based medical device manufacturer, announced that it has immediately begun producing new non-surgical masks for children in response to the COVID-19 pandemic.

Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in viral diseases, oncology and inflammation, announced today that the U.S. Food and Drug Administration (FDA) has approved a supplement